Efforts to develop targeted next-generation CF therapeutics will require new approaches to efficiently profile the sensitivity of clinical CF variants to emerging CFTR modulators (i.e. theratype) (McKee et al., 2023; Veit et al., 2021). The gene discussed is CFTR; the disease is cystic fibrosis.